As of December 15, 2025, Abbott Laboratories (ABT) reports a Forward P/E of 24.11.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Abbott Laboratories's Forward P/E to Peers
To better understand Abbott Laboratories's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Abbott Laboratories (ABT) | 24.11 |
| Penumbra Inc (PEN) | 80.48 |
| ABIOMED Inc (ABMD) | 77.58 |
| Intuitive Surgical Inc (ISRG) | 61.59 |
| Insulet Corp (PODD) | 59.64 |
| Dexcom Inc (DXCM) | 31.58 |
Compared to its competitors, Abbott Laboratories's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.